Evidence map›Paper›PMID 39428607›Full record

ArticleActa ophthalmologica2025

Influence of scleral thickness on photodynamic therapy outcomes in central serous chorioretinopathy.

Paolo Forte, Jennifer Cattaneo, Felice Cardillo Piccolino, Alessandro Arrigo, Paolo Corazza, Donatella Musetti, Raffaella Rosa, Carlo Enrico Traverso, Vincenzo Fontana, Marco Lupidi and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Paolo ForteEye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID https://orcid.org/0000-0003-1762-3506
Jennifer CattaneoDepartment of Ophthalmology, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Felice Cardillo PiccolinoDINOGMI, University of Genoa, Genoa, Italy.
Alessandro ArrigoFondazione Italiana Macula ETS, Genoa, Italy.
Paolo CorazzaEye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Donatella MusettiEye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Raffaella RosaEye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Carlo Enrico TraversoEye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Vincenzo FontanaClinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Marco LupidiFondazione Italiana Macula ETS, Genoa, Italy.
Chiara Maria EandiDepartment of Ophthalmology, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Massimo NicolòEye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Funding

Fondazione Italiana Macula ETS, Genoa, Italy
6 · The paper itself

Abstract

purposeTo test the prognostic role of anterior scleral substantia propria (ASSP) thickness in predicting the 3-month response after half-dose photodynamic therapy (PDT) in central serous chorioretinopathy (CSCR) and to assess its clinical relevance of ASSP in different CSCR phenotypes.

methodsA prospective, exploratory, multi-centre cohort study conducted at IRCCS San Martino Hospital (Genoa, Italy) and Jules-Gonin Eye Hospital (Lausanne, Switzerland). Demographic and clinical data, and optical coherence tomography (OCT) were collected at baseline and 3 months after PDT. Based on OCT images, we categorized CSCR phenotypes and collected clinically relevant imaging metrics. ASSP thickness was obtained from four different measurements using anterior segment (AS) OCT. Multivariable regression models were performed to evaluate the distribution of ASSP thicknesses among different CSCR phenotypes and to test the prognostic role of ASSP thickness in discriminating between PDT responders (complete subretinal fluid reabsorption) and partial responders.

resultsThe study cohort comprised 109 Caucasian patients (82 males, 75.2%) with a total of 142 eyes: 84 eyes simple (59.1%) versus 58 eyes complex (40.9%) CSCR. A linear normal model confirmed a positive association between complex CSCR and higher ASSP thickness (β = 26.1, 95% CL = 12.1/40.1, p < 0.001), with a low prevalence of ciliochoroidal effusion loculations in AS-OCT (1/142 eyes, 0.7%). ASSP thickening was positively linked to the presence of posterior cystoid retinal degeneration (PCRD; p = 0.002), indicating a potential role in the pathogenesis of severe CSCR phenotypes. In the subgroup of treated patients (61 eyes), 63.9% had a complete response after PDT. In these patients a logistic binary model highlighted a significantly higher risk of PDT non-responsiveness (OR = 9.62, 95% CL = 2.44/37.9, p = 0.001) associated with a 60-unit increase in ASSP thickness levels. By contrast, other anatomical parameters (i.e., body surface area, age, gender, axial length) showed no remarkable prognostic roles.

conclusionThis research highlighted the association of ASSP thickening with complex CSCR phenotype in Caucasian patients and its role in predicting PDT efficacy. These findings enhance our comprehension of the anatomical risk factors in patients affected with CSCR and potentially guide a better understanding of non-responsive cases to PDT treatment.

Indexed as

Central Serous ChorioretinopathyPhotochemotherapyScleraTomography, Optical CoherenceVerteporfinVisual AcuityAdultAgedFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansMaleMiddle AgedPhotosensitizing AgentsPhotosensitizing AgentsVerteporfinanterior segment optical coherence tomographycentral serous chorioretinopathychoroidal thicknessphotodynamic therapyscleral substantia propriascleral thickness

Identifiers

PMID39428607
PMCPMC11986406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.